OBI-3424
- Generic Name
- OBI-3424
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N4O6P
- CAS Number
- 2097713-68-1
- Unique Ingredient Identifier
- X6SH5T8H76
- Background
OBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)).
OBI Pharma's Novel TROP2 ADC OBI-902 Receives FDA IND Clearance for Phase 1/2 Trial Using Proprietary GlycOBI® Technology
• OBI Pharma announced FDA clearance of its IND application for OBI-902, a novel TROP2-targeting antibody-drug conjugate utilizing their proprietary GlycOBI® technology platform, with patient enrollment for Phase 1/2 trials expected in the second half of 2025.
• Preclinical data presented at AACR 2025 demonstrated OBI-902's superior antitumor activity, favorable pharmacokinetics, and enhanced stability compared to benchmark TROP2 ADCs across various animal models, positioning it as a potential best-in-class therapy.
• The GlycOBI® platform represents a breakthrough in ADC development with its site-specific glycan technology enabling versatile drug-antibody ratios up to 16 and dual payload conjugations, while the complementary ThiOBI® platform offers improved stability through irreversible cysteine conjugation.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath